References

Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets

10.1128/jvi.02681-13 · 2014 · External reference

Nextclade: clade assignment, mutation calling and quality control for viral genomes

10.21105/joss.03773 · 2021 · External reference

Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States

10.1093/aje/kwp237 · 2009 · External reference

Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic

10.1099/vir.0.017459-0 · 2010 · External reference

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern

10.1016/s0140-6736(05)67338-2 · 2005 · External reference

'Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses'

10.1371/journal.ppat.1004065 · 2014 · External reference

'Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs'

10.1002/jmv.23986 · 2015 · External reference

'Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses'

10.1016/j.antiviral.2008.08.008 · 2009 · External reference

'Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing'

10.1128/aac.01417-09 · 2010 · External reference

Atypical influenza A(H3N2) activity patterns in Germany, 2021-2023, and characterization of newly emerged virus clades

10.1002/jmv.70530 · 2025 · External reference

A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1

10.1016/j.jviromet.2008.07.017 · 2008 · External reference

Increase of synergistic secondary antiviral mutations in the evolution of A(H1N1)pdm09 influenza virus neuraminidases

10.3390/v16071109 · 2024 · External reference

'Prophylaxis and treatment of influenza: options, antiviral susceptibility, and existing recommendations'

2021 · External reference

Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany

10.1016/j.antiviral.2010.11.001 · 2011 · External reference

'Different populations of A(H1N1)pdm09 viruses in a patient with hemolytic-uremic syndrome'

10.1016/j.ijmm.2024.151598 · 2024 · External reference

The population impact of a large school-based influenza vaccination campaign

10.1371/journal.pone.0015097 · 2010 · External reference

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802

10.2165/00003088-199937060-00003 · 1999 · External reference

The epidemiology and spread of drug resistant human influenza viruses

10.1016/j.coviro.2014.04.009 · 2014 · External reference

Debate regarding oseltamivir use for seasonal and pandemic influenza

10.3201/eid2206.151037 · 2016 · External reference

Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation

10.2807/ese.16.23.19884-en · 2011 · External reference

Global update on the susceptibilities of influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2020-2023

10.1016/j.antiviral.2025.106217 · 2025 · External reference

Neuraminidase inhibitor resistance in influenza: a clinical perspective

10.1097/qco.0000000000000498 · 2018 · External reference

Global emergence of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses with I223V and S247N mutations: implications for antiviral resistance monitoring

10.1016/s2666-5247(24)00037-5 · 2024 · External reference

Overexpression of the -2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors

10.1128/jvi.77.15.8418-8425.2003 · 2003 · External reference

Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance

10.1111/irv.12047 · 2013 · External reference

Phylogenetic analysis and docking study of neuraminidase gene of influenza A/H1N1 viruses circulating in Iran from 2010 to 2019

10.1016/j.virusres.2023.199182 · 2023 · External reference

Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir

10.1086/656439 · 2010 · External reference

Trends in respiratory virus circulation following COVID-19-targeted nonpharmaceutical interventions in Germany, January - September 2020: analysis of national surveillance data

2021 · External reference

'Preparing for the next influenza season: monitoring the emergence and spread of antiviral resistance'

10.2147/idr.s389263 · 2023 · External reference

Multicountry spread of influenza A(H1N1)pdm09 viruses with reduced oseltamivir inhibition

2024 · External reference

Prospective surveillance of antiviral resistance in hospitalized infants less than 12 months of age with A(H3N2) influenza infection and treated with oseltamivir

10.3851/imp3141 · 2017 · External reference

Expansion of influenza A(H1N1)pdm09 NA:S247N viruses with reduced susceptibility to oseltamivir, Catalonia, Spain, and in Europe, July to October 2025

10.2807/1560-7917.es.2025.30.48.2500873 · 2025 · External reference

Summary of WHO clinical practice guidelines for influenza

10.1136/bmj-2025-087397 · 2026 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

H274Y's effect on oseltamivir resistance: what happens before the drug enters the binding site

10.1021/acs.jcim.5b00331 · 2016 · External reference